pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 493
- Drugs
- 98
- Patents
- 837
NTLA-2001
Phase 3 · mab · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
NTLA-2001 for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy is a Phase 3 program (mab) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Internal code ITL-2001-CL-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Regeneron UK Limited
- Phase
- Phase 3
- Modality
- mab
- Indication
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Status
- active
- Trials
- 1